Despite small sample size and the lack of pre-treatment control samples, these findings agree with previous reports describing increased PD-L1 expression in cancer tissues and peripheral blood T-lymphocytes after pembrolizumab- treatment [14, 15]. The gene discussed is CD274; the disease is cancer.